Uniqure N V (QURE) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Uniqure N v   (NASDAQ: QURE)


Uniqure N V's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Uniqure N V's ROI in the first quarter of 2026?
Uniqure N V recorded a cumulative net loss of $-209 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -29.7%.

Within the Healthcare sector 387 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 3477, from total ROI ranking in the fourth quarter of 2025 at 4079.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 20.51 % 7.72 % 7.35 % -10.69 % -14.13 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 720 762 788 544 569
Return On Investment (TTM) -29.7 % -29.89 % -38.59 % -35.73 % -37.28 %
QURE's Overall Ranking # 3477 # 4079 # 3729 # 3702 # 3755
Seq. Investment Change TTM 5.65 % 9.26 % 9.39 % -4.56 % -5.56 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -209 -199 -235 -199 -218

QURE Company Profile >> Back to QURE Roi Comparisons >> See Annual QURE Return On Investment



Return On Investment QURE's Ranking
Within: No.
Industry # 146
Sector # 388
Overall # 3477

Return On Investment Statistics
High Average Low
70.25 %
-27.74 %
-105.32 %
(Jun 30 2021)   (Dec 31 2017)



  News about Uniqure N v Return on Investment ROI

Pioneering Hope in Fabry Disease The First Patient Dosed in uniQure’s AMT-191 Clinical Trial,

August 15, 2024

: uniQure N.V., a frontrunner in gene therapy, has made significant strides in the treatment of Fabry disease with the initiation of its Phase I/IIa clinical trial for AMT-191. This article delves into the details of this key advancement, outlining the implications for the company and the broader landscape of rare disease therapeutics.Fabry disease is a rare, inherited lysosomal storage disorder impacting multiple organ systems and significantly reducing quality of life. With no curative therapies currently available, there is immense urgency to develop effective treatments. UniQure N.V., renowned for its innovative approaches to gene therapy, has taken a vital step forward by administering the first dose of AMT-191 in a Phase I/IIa clinical trial, representing the company’s commitment to addressing severe unmet medical needs.





Financial Statements
Uniqure N V's I. Quarter Investments $ 720 Millions QURE's Balance sheet
Uniqure N V's I. Quarter Income $ -54 Millions Quarterly QURE's Income Statement
QURE's Income by Division See QURE's Income by Division


QURE Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 785 536 335 654 795
Y / Y Investment Growth 46.44 % 60.23 % -48.78 % -17.82 % 176.81 %
Net Income in Millions -199 -240 -308 -127 330
Y / Y Net Income Growth - - - - -
Annual Return On Investment -25.33 % -44.66 % -92.15 % -19.4 % 41.45 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
QURE's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for QURE's Competitors
Subscribers only: Roi for Uniqure N V's Suppliers
Subscribers only: Return On Investment for QURE's Customers

Other Ratios
QURE's Roa QURE's Inventory Turnover Ratio QURE's Growth Rates QURE's Dividend Statistics
QURE's Profitability Ratios QURE's Asset Turnover Ratio QURE's Dividend Growth
QURE's Roe QURE's Valuation Ratios QURE's Financial Strength Ratios QURE's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:30:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.